Showing results (241-250 of 369) with videos related to

Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancerHoward I Scher, Xiaoyu Jia, Kim Chi, et al.
Archives of Pathology & Laboratory Medicine|October 9, 2018
Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate CancerLiana B Guedes, Carlos L Morais, Helen Fedor, et al.
Nature Reviews. Urology|July 9, 2026
Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancerSean A Fletcher, Nicholas A Pickersgill, Juan C Osorio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Susceptibility loci associated with prostate cancer progression and mortalityDavid J Gallagher, Joseph Vijai, Angel M Cronin, et al.
Prostate Cancer and Prostatic Diseases|February 26, 2020
Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancerSounak Gupta, Chad Vanderbilt, Wassim Abida, et al.
European Urology|June 13, 2016
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate CancerDavid Lorente, David Olmos, Joaquin Mateo, et al.
European Urology|March 12, 2016
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate CancerKarim Fizazi, Kim N Chi, Johann S de Bono, et al.
JCO Precision Oncology|August 29, 2020
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene AlterationsJose Mauricio Mota, Ethan Barnett, Jones T Nauseef, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug developmentGary J Kelloff, John M Hoffman, Bruce Johnson, et al.
The Lancet. Oncology|February 22, 2015
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trialFred Saad, Karim Fizazi, Viorel Jinga, et al.
Pageof 37